Key Highlights
•
A new oral form of the chemotherapy drug paclitaxel (called DHP107) was shown to be as effective as the standard intravenous version for treating advanced breast cancer. This is important because the oral pill could spare patients from lengthy IV infusions and reduce common side effects like severe allergic reactions and nerve damage.
Source →
•
For lung cancer patients with both an EGFR mutation and a mutation in a tumor suppressor gene, adding standard chemotherapy to the targeted drug aumolertinib significantly delayed cancer progression compared to the targeted drug alone. This finding provides the first evidence that a more aggressive, combination treatment approach can improve outcomes for this specific group of patients.
Source →
•
Triple-negative breast cancer cells that spread to different organs (metastasize) rely on unique combinations of nutrients available in those specific tissues, not just the level of a single nutrient. This discovery reveals the complex metabolic rules that govern where cancer spreads, which could lead to new strategies to block metastasis.
Source →
•
A new blood test measuring 32 proteins predicted who would develop chronic lung disease (COPD) much more accurately than a genetic risk score, and a simplified 10-protein version worked nearly as well. This advance could lead to a simple clinical tool for identifying high-risk individuals long before symptoms appear, allowing for earlier intervention.
Source →
•
People with the muscle-wasting disease facioscapulohumeral muscular dystrophy (FSHD) appear to develop the autoimmune condition myasthenia gravis more frequently than the general population, suggesting a novel link between the two disorders. Recognizing this association is crucial because myasthenia gravis is treatable, and timely diagnosis can prevent life-threatening complications.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
